Akeso, Inc. (HK:9926) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akeso, Inc. (HK:9926) has registered a new phase II trial called “A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe Asthma.” The study aims to see if AK139 can improve asthma control and safety in patients who remain symptomatic, which could open a new growth path in respiratory care.
The study tests AK139, a drug given by subcutaneous injection in three different dosing regimens, against a placebo injection. The goal is to reduce asthma flare ups and symptoms in moderate to severe patients, a group that often cycles through current biologics from larger pharma rivals.
The trial uses a randomized, double blind, parallel group design, meaning participants are randomly placed into AK139 or placebo arms and neither they nor investigators know which treatment they receive. The main purpose is treatment focused, so the key readouts will be how much AK139 improves breathing and lowers attacks versus placebo.
The study was first submitted on 2026-02-03, marking the formal start of the clinical push in this indication for Akeso. The latest update to the record was filed on 2026-02-25, and the trial is listed as not yet recruiting, signaling that site start up and regulatory work are still under way before dosing begins.
For investors, this update confirms Akeso is moving deeper into chronic immune diseases, an area where successful biologics can support premium pricing and recurring revenue. While phase II data are several years away, news of progress may support sentiment for HK:9926 versus global asthma leaders like AstraZeneca and GSK, especially if Akeso can show a clear edge in safety or convenience.
As the study remains in the start up phase and is officially ongoing in the registry, investors can track future amendments, recruitment status, and eventual results on the ClinicalTrials portal for more detailed updates.
To learn more about HK:9926’s potential, visit the Akeso, Inc. drug pipeline page.